Abstract: Rituximab(RTX) is a monoclonal antibody specific for CD20 antigens on B cells and has been approved by the National Medical Products Administration for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. In the clinical, RTX has been used in a variety of autoimmune-associated diseases, such as immune thrombocytopenia, Sjogren’s syndrome, systemic lupus erythematosus etc., all of which are beyond off-label drug use. The aim of this article is scientifically management of the off-label use of RTX based on international and domestic RTX medication instructions, guidelines, expert consensus, and trustworthy clinical trials.